Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study

Table 2 Hazard ratios (HRs) for the association of metabolic syndrome or hs-CRP levels with PLC risk

Group	Cases/ person-years	Crude models		Adjusted models
Group	Cases/ person-years	HR (95%CI)	P-value	HR (95%CI)	P-value
MetS metrics ^a
MetS-0	119/349088	Ref		Ref
MetS-1	161/418573	1.12(0.88,1.42)	0.345	1.16(0.91,1.48)	0.229
MetS-2	74/261098	0.83(0.62,1.11)	0.211	0.89(0.66,1.21)	0.465
MetS-3	33/91177	1.06(0.72,1.56)	0.761	1.36(0.90,2.05)	0.141
MetS-4 (5)	8/15120	1.55(0.76,3.17)	0.231	3.32(1.46,7.56)	0.004
P for trend			0.197		0.010
MetS ^a
0	354/1028759	Ref		Ref
1	41/106297	1.12(0.81,1.55)	0.479	1.45(1.03,2.04)	0.034
P for interaction ^b					0.078
Hs-CRP ^c
≤ 3 mg/L	299/936212	Ref		Ref
> 3 mg/L	96/198844	1.50(1.19,1.89)	< 0.001	1.47(1.17,1.86)	0.001
Hs-CRP (per SD)	395/1135056	1.04(0.98,1.10)	0.199	1.01(1.00,1.02)	0.222

Adjusted models were adjusted for age (10-year age classes), sex, family income, educational background, marital status, HBV infection, cirrhosis, fatty liver, BMI, TC, ALT, SUA, smoking status, drinking status, physical activity, sedentary lifestyle, tea consumption, salt intake, high-fat diet, family history of cancer
^a Further adjusted for hs-CRP group (≤ 3 vs. > 3)
^b Interaction between MetS and hs-CRP
^c Further adjusted for MetS